在NSCLC中致癌融合:从机制到临床应用
Nyein Wint Yee Theik1, Suset Almuinas De Armas1, Daniel Rosas2
1Memorial Healthcare System, Internal Medicine Residency Program, Pembroke Pines, FL 33028, USA.
针对性疗法,如氨酸激酶抑制剂 (TKIs),在由基因融合 (ALK,ROS1,RET,NTRK) 驱动的非小细胞肺癌 (NSCLC) 方面表现有前途. 研究继续解决诸如获得突变等挑战,以改善NSCLC治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 非小细胞肺癌 (NSCLC) 常常是由遗传改变驱动的.
- 包括ALK,ROS1,RET和NTRK在内的致癌融合在NSCLC瘤发生中起着至关重要的作用.
- 导致这些融合的染色体重组是关键的致癌驱动因素.
研究的目的:
- 审查癌症融合在NSCLC中的作用.
- 讨论向疗法的影响,如氨酸激酶抑制剂 (TKI),对NSCLC治疗.
- 突出NSCLC治疗中的挑战和未来研究方向.
主要方法:
- 关于NSCLC遗传变异和向疗法研究的文献综述.
- 分析常见的致癌融合及其信号通路.
- 评估氨酸激酶抑制剂 (TKI) 的疗效和挑战.
主要成果:
- 致癌融合是NSCLC的重要驱动因素,涉及ALK,ROS1,RET和NTRK等途径.
- 针对性疗法 (TKIs) 为NSCLC患者提供了比传统化疗更好的疗效和耐受性.
- 获得的突变是一个挑战,需要对优化NSCLC治疗进行持续研究.
结论:
- 针对特定基因融合的向疗法已经改变了NSCLC治疗.
- 了解瘤性融合等分子驱动因素对于NSCLC个性化医学至关重要.
- 持续的研究对于克服耐药机制和改善NSCLC患者的长期结果至关重要.
更多相关视频
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
